Sue Caleo-Naeyaert
Global Head Government Affairs, Policy and Pharmaceconomics
Fresenius Kabi SwissBioSim
Biosimilars Commercialisation Summit Agenda 2019
Conference Day Two
Thursday, March 5th, 2020
2:20 PM Patients and the Challenge of Switching
- Consider how a patient may feel powerless when being forced/ encouraged to switch to a biosimilar
- Discuss how the science behind a biosimilar, with respect to complexity, may add to patients skepticism and the importance to educate patients about their safety and efficacy to allay their fears
- Explore the commercial significance of switching, with respect to the necessity to switch established patients between brands to allow hospitals to avoid only using biosimilars for new treatment starts
3:25 PM Panel Discussion: The Market Value of Real World Evidence in the Education of Stakeholders
- Explore the contentious idea that real world evidence is an unnecessary undertaking in the commercialisation of biosimilars
- Consider the pros and cons of incremental registration for multiple indications
- Hear the views of a sponsoring company, pharmacist, and payer